Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publically traded biotechnology company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO).

from http://www.opexatherapeutics.com/

Patents 58show all

  • 19
    A61K - Preparations for medical, dental, or toilet purposes
  • 19
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 16
    C12N - Microorganisms or enzymes
  • 12
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 4
    C07K - Peptides

Clinical Trials 4show all

3Phase 21Phase 1/Phase 2

SEC Filings show all


234
8-K

37
10-Q

13
10-K

6
D

1
S-1

Contact Information

The Woodlands, TX
United States

SEC Form D Funding Events

DateOfferedSoldType
2013-02-19Indefinite$0Option to Acquire, Security to be Acquired
2013-02-19$650,000$650,000Debt, Option to Acquire, Security to be Acquired
2012-11-19$15,000,000$0Equity
2012-07-27$4,085,000$4,085,000Debt, Option to Acquire, Security to be Acquired
2009-04-27$2,000,000$1,101,000Other
2008-08-22Unknown Unknown Other (Paper Filing)

Key Executives

  • Neil K. Warma
    Executive Officer
  • David Hung
    Director
  • David B. McWilliams
    Director
  • David E. Jorden
    Director
  • Michael S. Richman
    Director
  • Scott B. Seaman
    Director
  • Gail J. Maderis
    Director
  • Donna R. Rill
    Executive Officer
  • Jaye L. Thompson
    Executive Officer